Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.